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ABSTRACT 
 
People believe that sumac is used as reducing fat. In the present study, the hypolipidemic effect of sumac fruits was 
compared with lovastatin in patients suffered hypercholesterolemia. In a randomized double-blinded-controlled 
trial, 172 patients diagnosed as hypercholesterolemia (high LDL level) and indicated for lipid-lowering schedules 
were randomly allocated to receive lovastatin (20 mg/day) or a combination of lovastatin (20 mg/day) and sumac (1 
gram equivalent to a teaspoon/day, soluble in water). Immediately before initial assessment and also after a 3-
month period of drugs prescription, the level of serum lipid profile was measured in both intervention groups by 
enzymatic assay and serum LDL level was determined using the Friedewald’s equation. At baseline, the mean level 
of LDL was 149.26±22.36 mg/dL in the group received combination therapy, and 146.25±19.89 mg/dL in the group 
received lovastatin alone with no significant different (p=0.352). However, following administration of the two 
treatment schedules, the level of LDL was significantly more reduced in combination treatment group compared 
with another group that the serum level of LDL after 3-month study period was 105.75±21.21 mg/dL in combination 
therapy group and 117.04±15.78 mg/dL in single therapy group (p<0.001). The positive response rate in the two 
groups was 93.0% and 75.6%, respectively (p=0.002). Using Multivariable logistic regression model, the use of 
sumac combined with statin led to higher response rate indicated by lowering serum LDL level (p=0.019). Sumac 
has a potential role in lowering LDL level especially when combined with anti-hyperlipidemic drugs as statins.  
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INTRODUCTION 
 
Medicinal plants and their derivatives are a rich resource for discovering new drugs [1-4]. In traditional medicine, 
they have been used for prevention of human disorders [5-12]. Also their effects have been investigated in various 
studies [13-19]. They have been shown the antioxidant activity, anti-inflammatory, anti-hyperlipidemic effects, etc. 
Sumac (Rhus coriaria L.), is one of the main medicinal plants from the family Anacardiaceae that the long history of 
its use has been noted in ancient medicine [20]. Sumac plant usually grows in subtropical and temperate regions 
throughout the world, especially in Africa, North America, and Southeast Asia [21]. In Iranian alternative medicine, 
sumac is used as a preventive agent in cardiac diseases and consumed with some common foods [22,23]. 
Phytochemical analysis have indicated that Sumac is a rich source of phenolic compounds, such as delphinidin, 
chrysanthemin, myrtillin, tannins, and some types of organic acids including malic acid, citric acid, and tartaric acid 
[24, 25]. Furthermore, some studies have shown a considerable amount of water-soluble tannins with antioxidant 
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properties effective for prevention of development and progression of cancer [26]. In addition, because of its 
phenolic acids, flavonols and anthocyanins components, it has been identified as a main source of phenolic 
compounds that act as antioxidants as well as a hypoglycemic agent. Recently, attentions have been focused on anti-
lipidemic properties of sumac so that long-term consumption of this herb has been accompanied with lowering 
serum lipids [27]. Also, glycoprotein extracted from sumac fruit result in decreasing serum cholesterol, triglyceride, 
and low-density lipoprotein (LDL) [28]. Because hyperlipidemia is a major risk factor for development of 
atherosclerosis and occurrence of new cardiac ischemic events, and also due to serious side effects of biochemical-
based drugs for lowering serum lipids, the use of a food additive and herbal medicine particularly for a long time is 
superior to achieve an appropriate level of serum lipid profile, leading reduced risk of coronary atherosclerosis and 
its life-threatening consequences. In the present study, the hypolipidemic effect of sumac fruits was compared with 
common used anti-lipidemic drugs in patients suffered hypercholesterolemia.  
 
MATERIALS AND METHODS 
 
In a randomized double-blinded-controlled trial, 172 consecutive patients diagnosed as hypercholesterolemia (high 
LDL level) and indicated for lipid-lowering schedules were entered into the study. The patients aged 40 to 80 years 
with a LDL cholesterol level of >or=130 mg/dl (>or=100 mg/dl if diabetes mellitus or cardiovascular disease was 
present) or on treatment. Those with the recent history of anti-lipids consumption, or suffered from any metabolic 
disturbances were excluded from the study. All participants were under a regular routine meal program. The study 
was performed according to the Declaration of Helsinki, and its protocol was approved by the Institutional Ethics 
Committee.  
 
According to the study protocol, the patients were randomly allocated to receive lovastatin (20 mg/day) or a 
combination of lovastatin (20 mg/day) and sumac (1 gram equivalent to a teaspoon/day, soluble in the warm water). 
Administered sumac for all subjects was purchased from a single location. Randomization was done by an 
independent investigator blinded to the type of drugs. Allocation also concealed using a random allocation chart. 
Immediately before initial assessment and also after a 3-month period of drugs prescription, the level of serum lipid 
profile was measured in both intervention groups by enzymatic assay and serum LDL level was determined using 
the Friedewald’s equation. Within the study time, none of the participants used other types of anti-lipid drugs. The 
end-point of the study was to compare the changes in serum LDL level between the interventional groups. The 
proper response rate to anti-lipid drugs was defined as “at least a 40 mg/dL decrease in LDL-C level following 
treatment”.  
 
Data were presented as mean ± SD for continuous variables and percentages for categorical variables. Comparisons 
of categorical variables across the groups were performed using an overall chi-square test or Fisher's exact test if 
required; while comparisons of continuous variables were performed using an independent t-test or Mann-Whitney 
U test. The difference in drug response rate was finally examined by the multivariable logistic regression modeling 
with the presence of baseline characteristics as probable confounders. P values of 0.05 or less were considered 
statistically significant. All the statistical analyses were performed using SPSS version 13 (SPSS Inc., Chicago, IL, 
USA).  
 
RESULTS AND DISCUSSION 
 
The two groups received combination therapy (including lovastatin and sumac) or single therapy (with lovastatin 
alone) were matched for baseline characteristics such as gender, age, body mass index, previous history of 
hypertension and diabetes mellitus, current smoking status, as well as for educational level (table 1).  
 
At baseline, the mean level of serum LDL was 149.26±22.36 mg/dL in group received combination therapy, and 
146.25±19.89 mg/dL with no significant different (p=0.352). However, following administration of the two 
treatment schedules, the level of serum LDL was significantly more reduced in combination treatment group 
compared with another group that the serum level of LDL after 3-month study period was 105.75 ± 21.21 mg/dL in 
combination therapy group and 117.04±15.78 mg/dL in single therapy group, p<0.001). In this regard, the positive 
response rate in the two groups was 93.0% and 75.6%, respectively (p=0.002). Using Multivariable logistic 
regression model (table 2), and considering a reduce at least a 40 mg/dL decrease in LDL-C level as positive 
response to treatment, the use of sumac combined with statin led to higher response rate indicated by lowering 
serum LDL level (OR=1.745, 95% CI: 1.094 – 2.786, p=0.019). 
Hamid Rouhi-Boroujeni et al Der Pharmacia Lettre, 2016, 8 (3):143-147 
______________________________________________________________________________ 
145 
Scholar Research Library 
Table 1: Baseline characteristics and clinical data in study subjects 
 
Characteristics  Lovastatin Group (n = 86) 
Lovastatin +Sumac group 
(n = 86) P-value 
Male gender 46 (53.5) 48 (55.8) 0.868 
Age (yr) 56.62 ± 7.79 58.35 ± 9.91 0.205 
History of hypertension 12 (14.0) 14 (16.3) 0.715 
History of diabetes mellitus 6 (7.0) 7 (8.1) 0.789 
Body mass index (kg/m2) 26.25 ± 3.32 26.02 ± 4.41 0.699 
current smoking 9 (10.5) 12 (14.0) 0.537 
Educational level    
Primary  18 (20.9) 16 (18.6) 0.754 
Secondary 42 (48.9) 40 (46.5) 0.856 
college degree 26 (30.2) 30 (34.9) 0.642 
 
Table 2: Multivariable logistic regression model for determining difference in response rate in the two interventional group 
 
Characteristics  Multivariate p-value Odds Ratio 95% Confidence Interval 
Drug pattern (L+S vs. L) 0.019 1.745 1.094 – 2.786 
Male gender 0.469 0.850 0.547 – 1.320 
Age  0.162 0.725 0.462 – 1.138 
History of hypertension 0.820 1.052 0.683 – 1.618 
History of diabetes mellitus 0.015 1.782 1.116 – 2.849 
Body mass index (kg/m2) 0.028 1.696 1.058 – 2.716 
Current smoking 0.352 1.261 0.773 – 2.056 
Educational level 0.655 1.115 0.691 – 1.801 
L: Lovastatin; S: Sumac. 
 
Various effects of sumac have been revealed in terms of its therapeutic effects as an antimicrobial and antioxidant 
[28]. The fruit of this plant has been also applied for improving fever, diarrhea, dermatitis and a variety of 
gastrointestinal disorders. The sumac plant serves also as a traditional medicine, which has pharmacological 
functions such as anti-hemorrhoidal, antiseptic, blood purifier, diuretic, stomachic and tonic [29, 30]. Despite 
different beneficial effects of this agent noted in ancient and also in modern medicines, up to now, few studies 
focused on its therapeutic effects on metabolic disturbances especially hypercholesterolemia as a main risk factor for 
cardiovascular disorders leading high mortality and morbidity whole of the world. The present study attempted to 
determine therapeutic impact of sumac as a lowering serum LDL level compared with common drug regimens such 
as statins. We aimed to consider sumac as a supplement to statin for reducing LDL level in hyperlipidemic patients 
and could show higher response rate to combination therapy compared to use statin alone. In a study, the plant 
extract raised markedly serum high-density lipoprotein (HDL) by 34% and also reduced low-density lipoprotein 
(HDL) by 32% [31]. Also showed that the treatment with aqueous methanol extract of sumac fruits reduced the 
serum lipids alterations observed in hypercholesterolemic animal models [32]. Oh et al. (2006) by extracting a 
special plant glycoprotein from sumac showed anti-hyperlipidemic effects of this agent along with its antioxidative 
characteristic. In total, the fruits of sumac can potentially reduce serum level of LDL and thus its administration in 
combined with anti-hyperlipidemic drugs such as statins can increased therapeutic response to these drugs 
effectively. On the other hand, by co-administration of statins and sumac, the need for elevating statin dosages or 
their use prolongation can be unnecessary and hence the side effects of these drugs may be significantly reduced 
[33]. According to few recent studies on the mechanisms of sumac for reducing serum lipids or related metabolism, 
lipid peroxidation had the main role in neutralizing processes involving increase of circulating lipids [34]. Lipid 
oxidation is a highly deteriorative process in foods, as it leads to unacceptable properties for the customer and a loss 
in nutritional value [35]. Various kinds of antioxidants with different functions inhibit lipid peroxidation and the 
deleterious effects caused by the lipid peroxidation products on different organs [36-47]. This effect is very vast, 
causing a wide variety of complications [48-52]. It should be noted that the biological role of lipid peroxidation 
products has recently received a great deal of attention, but its physiological significance remained unclear [53-55]. 
According to this fact that extracts and fractions of sumac have moderate lipid peroxidation inhibition effects, it 
seems that sumac not only has a major role for preventing lipid oxidation, it may also reduce lipid levels and thus 
prevent progression of cardiovascular disorders.  
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CONCLUSION 
 
In conclusion, along with antimicrobial and antioxidant effects of sumac, the level of serum lipids can be effectively 
reduced following use of this agent, especially in combination of anti-lipidemic drugs. On the other hand, adding 
this material to statins can strengthen drug efficacy to lowering serum LDL.     
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